Intercept Pharmaceuticals (ICPT) Files $75M IPO
Tweet Send to a Friend
Up)
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $75 million. The company plans to list on the Nasdaq Global Market under the ticker "ICPT."
The offering is being made through BofA Merrill Lynch, BMO Capital Markets, Needham & Company, Wedbush PacGrow, and Life Sciences.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through BofA Merrill Lynch, BMO Capital Markets, Needham & Company, Wedbush PacGrow, and Life Sciences.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
- Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
Create E-mail Alert Related Categories
IPOsRelated Entities
Merrill Lynch, Needham & Company, Bank of America, BMO Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
